Condition

Cervical cancer

Clinical trials and treatment information for Cervical cancer

3.4M
People Affected
200
Active Trials
1M
New Cases/Year
297K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Radical Hysterectomy
90% Effectiveness• 95% Confidence• 60% Safety• 99 trials• 100K participants
HIGH EvidenceExcellent ValueDose: N/A
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

Immediate

Duration

Single procedure, weeks for recovery

Response Rate

%

Remission Rate

85%

Common Side Effects:

Pain: 80%
Lymphedema: 15%
Infection: 8%
Bleeding/Hemorrhage: 4%
Bladder/Bowel injury: 2%
Vaginal shortening/dyspareunia: 30%

Annual Cost of Care

Drug Cost

$0

Monitoring

$2,000

Side Effects

$1,000

Total Annual

$40,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

7.5

Cost per Remission

$47,059

Treatment Outcomes
Primary Outcomes
5-year Overall Survival RateExpected 5-year OS for early-stage cervical cancer without radical hysterectomy: 60%
+41.67% (+25 percentage points)
5-year Disease-Free Survival RateExpected 5-year DFS for early-stage cervical cancer without radical hysterectomy: 50%
+60% (+30 percentage points)
Loco-regional Recurrence RateExpected 5-year loco-regional recurrence rate for early-stage cervical cancer without radical hysterectomy: 20%
-75% (-15 percentage points)
Secondary Benefits
Cervical Cancer-related Symptom BurdenEORTC QLQ-C30 symptom scale score: 60/100 (higher score indicates worse symptoms)
-66.67% (-40 points)
Hemoglobin levels10.5 g/dL (mild anemia due to chronic bleeding from tumor)
+23.81% (+2.5 g/dL)
Physical FunctioningEORTC QLQ-C30 Physical Functioning score: 50/100 (higher score indicates better function)
+60% (+30 points)
Common Side Effects
Pain
+80%
Lymphedema
+15%
Infection
+8%

Clinical Trial Phases:

Phase 4
2
Concurrent Chemoradiation (Cisplatin-based)
85% Effectiveness• 95% Confidence• 25% Safety• 67 trials• 50K participants
HIGH EvidenceGood ValueDose: Cisplatin 40mg/m² weekly for 5-6 cycles, plus EBRT and brachytherapy
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

During and shortly after treatment

Duration

5-7 weeks

Response Rate

80%

Remission Rate

65%

Number Needed to Treat (NNT)

6

Common Side Effects:

Fatigue: 85%
Nausea/Vomiting: 75%
Diarrhea/Proctitis: 60%
Cystitis: 40%
Bone marrow suppression: 50%
Peripheral neuropathy: 30%
Sexual dysfunction/Vaginal stenosis: 60%

Annual Cost of Care

Drug Cost

$1,000

Monitoring

$10,000

Side Effects

$6,000

Total Annual

$50,000

Cost-Effectiveness

GOOD

QALYs Gained

3

ICER

$60,000/QALY

Cost per Remission

$76,923

Cost per Responder

$62,500

Treatment Outcomes
Primary Outcomes
5-year Overall Survival Rate65%
+15.38% (+10 percentage points)
5-year Progression-Free Survival Rate55%
+21.82% (+12 percentage points)
Local Regional Control Rate (at 5 years)70%
+21.43% (+15 percentage points)
Complete Response Rate (post-treatment)75%
+20% (+15 percentage points)
Secondary Benefits
Global Health Status/QoL (EORTC QLQ-C30, 0-100)55/100
+21.82% (+12 points)
Pain Score (VAS 0-10, higher is worse)6.5/10
-46.15% (-3 points)
Physical Functioning (EORTC QLQ-C30, 0-100)60/100
+16.67% (+10 points)
Common Side Effects
Fatigue
+85%
Nausea/Vomiting
+75%
Diarrhea/Proctitis
+60%

Clinical Trial Phases:

Phase 3Phase 4
3
Radiation Therapy (EBRT + Brachytherapy)
80% Effectiveness• 95% Confidence• 25% Safety• 101 trials• 100K participants
HIGH EvidenceGood ValueDose: EBRT 45-50 Gy, Brachytherapy 20-30 Gy
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

During and shortly after treatment

Duration

5-7 weeks

Response Rate

80%

Remission Rate

60%

Common Side Effects:

Fatigue: 75%
Diarrhea/Proctitis: 60%
Cystitis: 40%
Vaginal stenosis/dryness: 70%
Bowel obstruction (late): 8%

Annual Cost of Care

Drug Cost

$0

Monitoring

$5,000

Side Effects

$3,000

Total Annual

$45,000

Cost-Effectiveness

GOOD

QALYs Gained

5.5

Cost per Remission

$75,000

Cost per Responder

$56,250

Treatment Outcomes
Primary Outcomes
Pelvic Pain Score7/10 on Numeric Rating Scale (NRS)
-71.4% (-5 points on NRS)
Vaginal Bleeding Severity7/10 on Symptom Severity Scale
-85.7% (-6 points on Symptom Severity Scale)
Primary Tumor Largest Dimension4.5 cm
-77.8% (-3.5 cm)
Serum CA-125 Levels180 U/mL
-83.3% (-150 U/mL)
Secondary Benefits
EORTC QLQ-C30 Global Health Status Score50/100
+20% (+10 points on QLQ-C30 GHS)
ECOG Performance Status2/5
-50% (-1 point on ECOG scale)
Hemoglobin Levels10.0 g/dL
+15% (+1.5 g/dL)
Common Side Effects
Fatigue
+75%
Diarrhea/Proctitis
+60%
Cystitis
+40%

Clinical Trial Phases:

Phase 3Phase 4
4
Cisplatin + Paclitaxel + Bevacizumab
50% Effectiveness• 90% Confidence• 25% Safety• 35 trials• 5K participants
HIGH EvidencePoor ValueDose: Cisplatin 50mg/m², Paclitaxel 135mg/m², Bevacizumab 15mg/kg every 3 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Weeks to months

Duration

Until progression or unacceptable toxicity

Response Rate

45%

Remission Rate

5%

Number Needed to Treat (NNT)

7

Number Needed to Harm (NNH)

15

Common Side Effects:

Fatigue: 85%
Nausea/Vomiting: 75%
Hair loss: 85%
Peripheral neuropathy: 60%
Bone marrow suppression: 70%
Hypertension: 40%
Gastrointestinal perforation: 3%
Fistula formation: 12%

Annual Cost of Care

Drug Cost

$100,000

Monitoring

$15,000

Side Effects

$8,000

Total Annual

$123,000

Cost-Effectiveness

POOR

QALYs Gained

1

ICER

$250,000/QALY

Cost per Responder

$273,333

Treatment Outcomes
Primary Outcomes
Overall Survival (median)13.3 months (for chemotherapy alone)
+26.3% (+3.5 months)
Progression-Free Survival (median)5.5 months (for chemotherapy alone)
+49.1% (+2.7 months)
Overall Response Rate36.7% (for chemotherapy alone)
+33% (+12.1 percentage points)
Secondary Benefits
Quality of Life (FACT-G total score)85 points (on a 0-108 scale, higher is better)
+5.9% (+5 points)
Pain Intensity (NRS/VAS)5/10 (Numerical Rating Scale)
-40% (-2 points)
Common Side Effects
Fatigue
+85%
Nausea/Vomiting
+75%
Hair loss
+85%

Clinical Trial Phases:

Phase 3Phase 4
5
Pembrolizumab
45% Effectiveness• 90% Confidence• 40% Safety• 457 trials• 3K participants
HIGH EvidencePoor ValueDose: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe

Time to Effect

Weeks to months

Duration

Until progression or up to 2 years

Response Rate

25%

Remission Rate

3%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

15

Common Side Effects:

Fatigue: 45%
Nausea: 25%
Diarrhea: 20%
Rash: 18%
Pruritus: 12%
Immune-related adverse events: 10%

Annual Cost of Care

Drug Cost

$180,000

Monitoring

$10,000

Side Effects

$5,000

Total Annual

$195,000

Cost-Effectiveness

POOR

QALYs Gained

0.6

ICER

$350,000/QALY

Cost per Responder

$780,000

Treatment Outcomes
Primary Outcomes
Overall Survival (Median)16.5 months (with standard chemotherapy)
+73.3% (+12.1 months)
Progression-Free Survival (Median)8.2 months (with standard chemotherapy)
+26.8% (+2.2 months)
Objective Response Rate (ORR)50% (with standard chemotherapy)
+36% (+18 percentage points)
Secondary Benefits
Disease Control Rate (CR+PR+SD)73% (with standard chemotherapy)
+12.3% (+9 percentage points)
Complete Response Rate (CRR)11% (with standard chemotherapy)
+72.7% (+8 percentage points)
12-Month Overall Survival Rate64.9% (with standard chemotherapy)
+18.3% (+11.9 percentage points)
Common Side Effects
Fatigue
+45%
Nausea
+25%
Diarrhea
+20%

Clinical Trial Phases:

Phase 3Phase 4